Related Experiment Video

Updated: Aug 9, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Targeting HER1/EGFR in cancer therapy: experience with erlotinib

Giuseppe Giaccone1

  • 1Vrije Universiteit Medical Center, Head of Division of Medical Oncology, 1117 De Boelelaan, Amsterdam, The Netherlands. g.giaccone@vumc.nl

Future Oncology (London, England)
|March 25, 2006
PubMed

Insights

Erlotinib, a targeted therapy drug, effectively inhibits human epidermal growth factor receptor 1/epidermal growth factor receptor (HER1/EGFR) tyrosine kinase activity. This drug has shown significant survival benefits in patients with non-small-cell lung and pancreatic cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The human epidermal growth factor receptor 1/epidermal growth factor receptor (HER1/EGFR) plays a crucial role in tumor growth and development.
  • Targeting HER1/EGFR signaling is a key strategy in modern cancer therapy.

Purpose of the Study:

  • To evaluate the efficacy of erlotinib, a HER1/EGFR tyrosine kinase inhibitor, in treating solid tumors.
  • To assess the impact of erlotinib on patient survival in non-small-cell lung cancer and pancreatic cancer.

Main Methods:

  • Erlotinib was investigated as a potent, selective, and reversible inhibitor of HER1/EGFR tyrosine kinase activity.
  • Clinical activity was assessed across various solid tumors.
  • Phase III trials were conducted to evaluate survival improvements.

Main Results:

  • Erlotinib demonstrated clinical activity in a range of solid tumors.
  • Significant improvements in survival were observed in patients with non-small-cell lung cancer.
  • Erlotinib also showed survival benefits in patients with pancreatic cancer.

Conclusions:

  • Erlotinib is an effective therapeutic agent targeting HER1/EGFR in cancer treatment.
  • The drug offers significant survival advantages for patients with non-small-cell lung and pancreatic cancers.
  • Targeted inhibition of HER1/EGFR represents a promising approach in oncology.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...